INCREASED LEVELS OF PROINFLAMMATORY CYTOKINES IN BLOOD PLASMA IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION

Highlights

IL-8 and MCP-1 have a significant role in the CTEPH pathogenesis, which indicates the importance of nonspecific immunity in the formation and progression of CTEPH. The coupling between cytokines and hemodynamic parameters, cardiac structural changes and plasma biochemical parameters were determined.

Abstract

Background. Chronic thromboembolic pulmonary hypertension (CTEPH) pathogenesis is complex and not fully understood. Particular attention to the microvascular damage genesis in CTEPH is given to aseptic inflammation, which in turn could be mediated through various molecular mechanisms. According to the conflicting and incomplete data on changes in the profile of factors controlling inflammation in CTEPH, research in this field would identify new therapeutic targets for the prevention and treatment of CTEPH.

Aim. To study the profile of plasma proinflammatory cytokines in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and evaluate the coupling of these cytokines with the main morphofunctional and laboratory values of the disease severity.

Methods. 34 patients with CTEPH were included in this study. To characterize the group, the following methods were used: echocardiographic examination, catheterization of the right cardiac chambers. Biomarkers of heart failure, systemic inflammation, as well as erythropoiesis and iron metabolism were assessed in all patients. The control group included 10 donors. To study the proinflammatory cytokine profile in plasma, interleukins (IL) 6, 8, 18, monocyte chemoattractant protein-1 (MCP-1) and matrix metalloproteinase 9 were determined using standard enzyme-linked immunosorbent assay (ELISA) kits.

Results. Hemodynamic and morphofunctional changes in the pulmonary circulation specific to pulmonary hypertension were determined with catheterization of the right cardiac chambers and echocardiography. During plasma proinflammatory cytokines analysis, a significant increase in the level of IL-8 (p = 0.030) and MCP-1 (p = 0.031) in CTEPH group compared to the control group was observed. No significant differences for other analyzed markers were found. In the elaboration of the correlation analysis, moderate inverse coupling between proinflammatory markers and hemodynamic parameters characterizing the CTEPH severity were revealed, as well as positive correlations with parameters of remodeling of the right cardiac chambers and iron metabolism.

Conclusion. The increased levels of IL-8 and MCP-1 in patients with CTEPH identified in the present study indicate a significant role of nonspecific immunity in the formation and progression of CTEPH. The coupling between cytokines and hemodynamic parameters, structural cardiac changes and plasma biochemical parameters were determined. Based on the obtained data, it is possible to develop new medicinal substances, targeting towards proinflammatory cytokines, their receptors and signaling pathways.

1. Konstantinides S.V., Meyer G. The 2019 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism. Eur Heart J. 2019; 40(42):3453-3455. doi:10.1093/eurheartj/ehz726

2. Moser K.M., Bloor C.M. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest. 1993; 103(3):685-692. doi:10.1378/chest.103.3.685

3. Simonneau G., Torbicki A., Dorfmüller P., Kim N. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017; 26(143):160112. doi:10.1183/16000617.0112-2016

4. Pietra G.G., Capron F., Stewart S., Leone O., Humbert M., Robbins I.M., Reid L.M., Tuder R.M. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004; 43(12 Suppl S):25S-32S. doi: 10.1016/j.jacc.2004.02.033

5. Lang I.M., Dorfmüller P., Vonk Noordegraaf A. The Pathobiology of Chronic Thromboembolic Pulmonary Hypertension. Ann Am Thorac Soc. 2016; 13 Suppl 3:S215-S221. doi: 10.1513/AnnalsATS.201509-620AS

6. Otani N., Watanabe R., Tomoe T., Toyoda S., Yasu T., Nakamoto T. Pathophysiology and Treatment of Chronic Thromboembolic Pulmonary Hypertension. Int J Mol Sci. 2023; 24(4):3979. doi: 10.3390/ijms24043979

7. Simonneau G., Dorfmüller P., Guignabert C., Mercier O., Humbert M. Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology. Ann Cardiothorac Surg. 2022; 11(2):106-119. doi: 10.21037/acs-2021-pte-10

8. Vrigkou E., Tsantes A., Konstantonis D., Rapti E., Maratou E., Pappas A., Halvatsiotis P., Tsangaris I. Platelet, Fibrinolytic and Other Coagulation Abnormalities in Newly-Diagnosed Patients with Chronic Thromboembolic Pulmonary Hypertension. Diagnostics (Basel). 2022; 12(5):1238. doi: 10.3390/diagnostics12051238

9. Yan L., Li X., Liu Z., Zhao Z., Luo Q., Zhao Q., Jin Q., Yu X., Zhang Y. Research progress on the pathogenesis of CTEPH. Heart Fail Rev. 2019; 24(6):1031-1040. doi: 10.1007/s10741-019-09802-4

10. Quarck R., Wynants M., Verbeken E., Meyns B., Delcroix M. Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension. Eur Respir J. 2015; 46(2):431-443. doi: 10.1183/09031936.00009914

11. Koudstaal T., Boomars K.A., Kool M. Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective. J Clin Med. 2020; 9(2):561. doi: 10.3390/jcm9020561

12. Zabini D., Heinemann A., Foris V., Nagaraj C., Nierlich P., Bálint Z., Kwapiszewska G., Lang I.M., Klepetko W., Olschewski H., Olschewski A. Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients. Eur Respir J. 2014; 44(4):951-962. doi: 10.1183/09031936.00145013

13. Koudstaal T., van Uden D., van Hulst J.A.C., Heukels P., Bergen I.M., Geenen L.W., Baggen V.J.M., van den Bosch A.E., van den Toorn L.M., Chandoesing P.P., Kool M., Boersma E., Hendriks R.W., Boomars K.A. Plasma markers in pulmonary hypertension subgroups correlate with patient survival. Respir Res. 2021; 22(1):137. doi: 10.1186/s12931-021-01716-w

14. Reesink H.J., Meijer R.C., Lutter R., Boomsma F., Jansen H.M., Kloek J.J., Bresser P. Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Circ J. 2006; 70(8):1058-1063. doi: 10.1253/circj.70.1058

15. Yang M., Deng C., Wu D., Zhong Z., Lv X., Huang Z., Lian N., Liu K., Zhang Q. The role of mononuclear cell tissue factor and inflammatory cytokines in patients with chronic thromboembolic pulmonary hypertension. J Thromb Thrombolysis. 2016; 42(1):38-45. doi: 10.1007/s11239-015-1323-2

16. Avdeev S.N., Barbarash O.L., Bautin A.E., Volkov A.V., Veselova T.N., Galyavich A.S., Goncharova N.S., Gorbachevsky S.V., Danilov N.M., Eremenko A.A., Martynyuk T.V., Moiseeva O.M., Saidova M.A., Sergienko V.B., Simakova M.A., Stukalova O.V., Chazova I.E., Chernyavsky A.M., Shalaev S.V., Shmalts A.A., Tsareva N.A. 2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2021; 26(12):4683. (In Russ.) doi:10.15829/1560-4071-2021-4683

17. Rudski L.G., Lai W.W., Afilalo J., Hua L., Handschumacher M.D., Chandrasekaran K., Solomon S.D., Louie E.K., Schiller N.B. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010; 23(7):685-788. doi: 10.1016/j.echo.2010.05.010

18. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1):111-117. doi: 10.1164/ajrccm.166.1.at1102

19. White C.A., Akbari A., Doucette S., Fergusson D., Knoll G.A. Estimating glomerular filtration rate in kidney transplantation: is the new chronic kidney disease epidemiology collaboration equation any better? Clin Chem. 2010; 56(3):474-477. doi: 10.1373/clinchem.2009.135111

20. Humbert M., Kovacs G., Hoeper M.M., Badagliacca R., Berger R.M.F., Brida M., Carlsen J., Coats A.J.S., Escribano-Subias P., Ferrari P., Ferreira D.S., Ghofrani H.A., Giannakoulas G., Kiely D.G., Mayer E., Meszaros G., Nagavci B., Olsson K.M., Pepke-Zaba J., Quint J.K., Rådegran G., Simonneau G., Sitbon O., Tonia T., Toshner M., Vachiery J.L., Vonk Noordegraaf A., Delcroix M., Rosenkranz S.; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43(38):3618-3731. doi: 10.1093/eurheartj/ehac237

21. Mukaida N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol. 2003; 284(4):L566-L577. doi: 10.1152/ajplung.00233.2002

22. Singh S., Anshita D., Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol. 2021; 101(Pt B):107598. doi: 10.1016/j.intimp.2021.107598

23. Kimura H., Okada O., Tanabe N., Tanaka Y., Terai M., Takiguchi Y., Masuda M., Nakajima N., Hiroshima K., Inadera H., Matsushima K., Kuriyama T. Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2001; 164(2):319-324. doi: 10.1164/ajrccm.164.2.2006154

24. Smolders V.F.E.D., Lodder K., Rodríguez C., Tura-Ceide O., Barberà J.A., Jukema J.W., Quax P.H.A., Goumans M.J., Kurakula K. The Inflammatory Profile of CTEPH-Derived Endothelial Cells Is a Possible Driver of Disease Progression. Cells. 2021; 10(4):737. doi: 10.3390/cells10040737

25. Xiao L., Liu Y., Wang N. New paradigms in inflammatory signaling in vascular endothelial cells. Am J Physiol Heart Circ Physiol. 2014; 306(3):H317-H325. doi: 10.1152/ajpheart.00182.2013

26. Wu D., Chen Y., Wang W., Li H., Yang M., Ding H., Lv X., Lian N., Zhao J., Deng C. The role of inflammation in a rat model of chronic thromboembolic pulmonary hypertension induced by carrageenan. Ann Transl Med. 2020; 8(7):492. doi: 10.21037/atm.2020.02.86

27. Åberg M., Björklund E., Wikström G., Christersson C. Platelet-leukocyte aggregate formation and inflammation in patients with pulmonary arterial hypertension and CTEPH. Platelets. 2022; 33(8):1199-1207. doi: 10.1080/09537104.2022.2087867

28. Magoń W., Stępniewski J., Waligóra M., Jonas K., Przybylski R., Podolec P., Kopeć G. Changes in Inflammatory Markers in Patients with Chronic Thromboembolic Pulmonary Hypertension Treated with Balloon Pulmonary Angioplasty. Cells. 2022; 11(9):1491. doi: 10.3390/cells11091491

29. Itoh T., Nagaya N., Ishibashi-Ueda H., Kyotani S., Oya H., Sakamaki F., Kimura H., Nakanishi N. Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology. 2006; 11(2):158-163. doi: 10.1111/j.1440-1843.2006.00821.x

30. Liu K., Zhang C., Chen B., Li M., Zhang P. Association between right atrial area measured by echocardiography and prognosis among pulmonary arterial hypertension: a systematic review and meta-analysis. BMJ Open. 2020; 10(9):e031316. doi: 10.1136/bmjopen-2019-031316

31. Zhang M., Zhang Y., Pang W., Zhai Z., Wang C. Circulating biomarkers in chronic thromboembolic pulmonary hypertension. Pulm Circ. 2019; 9(2):2045894019844480. doi: 10.1177/2045894019844480

32. Wynants M., Quarck R., Ronisz A., Alfaro-Moreno E., Van Raemdonck D., Meyns B., Delcroix M. Effects of C-reactive protein on human pulmonary vascular cells in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2012; 40(4):886-894. doi: 10.1183/09031936.00197511

33. Quarck R., Nawrot T., Meyns B., Delcroix M. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 53(14):1211-1218. doi: 10.1016/j.jacc.2008.12.038

34. Skoro-Sajer N., Gerges C., Gerges M., Panzenböck A., Jakowitsch J., Kurz A., Taghavi S., Sadushi-Kolici R., Campean I., Klepetko W., Celermajer D.S., Lang I.M. Usefulness of thrombosis and inflammation biomarkers in chronic thromboembolic pulmonary hypertension-sampling plasma and surgical specimens. J Heart Lung Transplant. 2018; 37(9):1067-1074. doi: 10.1016/j.healun.2018.04.003

35. Wessling-Resnick M. Iron homeostasis and the inflammatory response. Annu Rev Nutr. 2010; 30:105-122. doi: 10.1146/annurev.nutr.012809.104804

36. Anand I.S., Gupta P. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. Circulation. 2018; 138(1):80-98. doi: 10.1161/CIRCULATIONAHA.118.030099

37. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113(9):1271-1276. doi: 10.1172/JCI20945

38. Lee P., Peng H., Gelbart T., Wang L., Beutler E. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A. 2005; 102(6):1906-1910. doi: 10.1073/pnas.0409808102

39. Sow F.B., Florence W.C., Satoskar A.R., Schlesinger L.S., Zwilling B.S., Lafuse W.P. Expression and localization of hepcidin in macrophages: a role in host defense against tuberculosis. J Leukoc Biol. 2007; 82(4):934-945. doi: 10.1189/jlb.0407216

40. Quatredeniers M., Mendes-Ferreira P., Santos-Ribeiro D., Nakhleh M.K., Ghigna M.R., Cohen-Kaminsky S., Perros F. Iron Deficiency in Pulmonary Arterial Hypertension: A Deep Dive into the Mechanisms. Cells. 2021; 10(2):477. doi: 10.3390/cells10020477

41. Valenti L., Dongiovanni P., Motta B.M., Swinkels D.W., Bonara P., Rametta R., Burdick L., Frugoni C., Fracanzani A.L., Fargion S. Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol. 2011; 31(3):683-690. doi: 10.1161/ATVBAHA.110.214858